Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.48 |
| ▸ | ITK | Q08881 | 2/20 | 0.42 |
| ▸ | VCP | P55072 | 5/20 | 0.41 |
| ▸ | IDH1 | O75874 | 3/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421146 | 0.90 | CDK5 (0.48) | CYP19A1CDK5CDK5R1ITKIDH1 | |
| SCHEMBL1422651 | 0.82 | SMN1; SMN2 (0.48) | CDK5CDK5R1ITKRETMAPT | |
| SCHEMBL1421592 | 0.82 | TDO2 (0.53) | ITKVCPMAPT | |
| SCHEMBL1484040 | 0.81 | CYP19A1 (0.62) | CYP19A1CDK5CDK5R1ITKVCP | |
| SCHEMBL3299142 | 0.81 | CDK5 (0.56) | CDK5CDK5R1MAPTRIPK1 | |
| SCHEMBL13577803 | 0.81 | MAPT (0.44) | CDK5CDK5R1MAPTRIPK1 | |
| SCHEMBL1420994 | 0.81 | CYP19A1 (0.52) | CYP19A1CDK5CDK5R1MAPT | |
| SCHEMBL1483699 | 0.79 | KDM4E (0.57) | ITKIDH1CCNB2CDK1CCNB1 | |
| SCHEMBL15058859 | 0.78 | CYP19A1 (0.81) | CYP19A1CDK5CDK5R1ITKVCP | |
| SCHEMBL15073406 | 0.76 | CYP19A1 (0.72) | CYP19A1CDK5CDK5R1ITKVCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | claimed |
| EP-2296474-A1 | NOVEL SUBSTITUTED INDOLES | Merck Sharp & Dohme Corp. (US) | 2011-03-23 | — | — | EP | claimed |
| WO-2009155024-A1 | NOVEL SUBSTITUTED INDOLES | MERCK & CO., INC. (US) | 2009-12-23 | — | — | WO | claimed |
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | disclosed |
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | disclosed |
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110076230-A1 | Novel Substituted Indoles | APP, BACE1, PSEN1 | CYP19A1 3222/4885CDK5 772/4885CDK5R1 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.